Behzad Najafian, MD
Anatomic Pathology · Seattle, WANPI 1831246644
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.4%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 4 manufacturers reported payments, led by Sanofi at 40.2% of the total. Reporting peaked in 2024 at $31,184 and has fallen 91.9% since, to $2,532 in 2025.
Across 41 payments — averaging $2007.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$33K
- Sanofi-aventis U.S. LLC$28K
- Amicus Therapeutics, Inc.$15K
- Spark Therapeutics, Inc.$6K
Across 16 payments — averaging $88,221 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$910K
- Amicus Therapeutics, Inc.$489K
- Sanofi US Services Inc.$12K
What the payments were for
- Consulting fees$39,05447%
- Speaking & faculty fees$17,44821%
- Travel & lodging$24,56930%
- Food & beverage$1,2572%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 23 | $33,121 |
| Sanofi-aventis U.S. LLC | 8 | $27,876 |
| Amicus Therapeutics, Inc. | 8 | $15,097 |
| Spark Therapeutics, Inc. | 2 | $6,233 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few anatomic pathology providers in Washingtonto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other anatomic pathology in Seattle
- Monica DebacaSeattle$323K
- Michael HaffnerSeattle$14K
- Cheung ChhiengSeattle$2K
- Aashiyana KoreishiSeattle$322
- Paul EdmonsonSeattle$297
- Haodong XuSeattle$132
- Shreeram AkileshSeattle$127
- Rebeca AlvarezSeattle$90
- Jey-Hsin ChenSeattle$33
- Patrick CiminoSeattle$25
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.